The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2022
Filed:
Jun. 22, 2018
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Msd R&d (China) Co., Ltd., Shanghai, CN;
John J. Acton, III, Bridgewater, NJ (US);
Jianming Bao, San Mateo, CA (US);
Qiaolin Deng, Princeton, NJ (US);
Melissa Egbertson, Ambler, PA (US);
Ronald Ferguson, II, Scotch Plains, NJ (US);
Xiaolei Gao, Bridgewater, NJ (US);
Scott Timothy Harrison, Elkins Park, PA (US);
Timothy J. Henderson, Natick, MA (US);
Sandra L. Knowles, Princeton, NJ (US);
Chunsing Li, Shanghai, CN;
Michael Man-Chu Lo, Bedminster, NJ (US);
Robert D. Mazzola, Jr., Stewartsville, NJ (US);
Meng Na, Shanghai, CN;
Michael T. Rudd, Collegeville, PA (US);
Oleg B. Selyutin, West Windsor, NJ (US);
David M. Tellers, Lansdale, PA (US);
Ling Tong, Warren, NJ (US);
Fengqi Zhang, Edison, NJ (US);
Takao Suzuki, Shanghai, CN;
Merck Sharp & Dohme Corp., Rahway, NJ (US);
MSD R&D (China) Co., Ltd., Shanghai, CN;
Abstract
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.